ClinicalTrials.gg
CompletedNCT04024332Updated Sep 3, 2020

Study of the Way the Body Takes up, Distributes, and Gets Rid of ACT-541468 in Subjects With Abnormal Kidney Function Compared to Healthy Subjects

A Phase 1 interventional study of ACT-541468 in Renal Insufficiency and Healthy, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 1 site in Germany. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-03.

Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 139 studies in Renal Insufficiency with a site in Germany — 12 open to participants now, 16 under way, 2 of them phase 3. Renal Insufficiency · Germany.

Enrollment
102nd of 113
16 · median 42
Started
2019
with 6 others
Phase 1
54 of 139
1 open now
Registered
94th of 139
by date

Among the 139 studies in Renal Insufficiency with a site in Germany, this one is the 102nd largest by enrollment of the 113 interventional ones that give a count, is one of 7 that started in 2019, is one of 54 in phase 1, and was the 94th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 145 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

12 of the 139 studies in Renal Insufficiency with a site in Germany are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 91 Renal Insufficiency studies recruiting now, 48 (53%) set no upper age limit and 18 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Renal Insufficiency with a site in Germany, or all of them as a file.
02

Study summary

Study of the way the body takes up, distributes, and gets rid of ACT-541468 in subjects with abnormal kidney function compared to healthy subjects

03

Conditions studied

  • Renal Insufficiency
  • Healthy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

General inclusion criteria for all subjects:

  • Signed in the local language prior to any study mandated procedure.
  • Male and female subjects aged 18 to 85 years (inclusive) at screening.
  • (BMI) from 18 to 35 kg/m2 (inclusive) at screening. Body weight at least 50 kg.
  • Women of : Women must have a negative serum pregnancy test at screening and a negative urine pregnancy test on Day -1. They must consistently and correctly use (during the entire study and 30 days thereafter) a highly effective method of with a failure rate of \< 1% per year.
  • Women of non-childbearing potential, i.e., , XY genotype, Turner syndrome, uterine agenesis: no contraceptive requirement.

Additional inclusion criteria for healthy subjects (Group A):

  • Normal renal function as confirmed based on (CLcr) by the Cockcroft-Gault equation adjusted for age: >= 80 mL/min for subjects \<= 50 years of age; >= 70 mL/min for subjects 51-60 years of age; >= 60 mL/min for subjects 61-85 years of age; CLcr = ([140-age(years)]×weight (kg))/(72×serum creatinine (mg/dL)) (x 0.85 for female subjects)
  • The CLcr value should be confirmed (± 25%) on Day -1 in case subjects will be dosed more than 10 days after the day of screening.
  • Hematology, clinical chemistry, and urinalysis test results not deviating from the normal range to a extent at screening.
  • Each healthy subject must be matched with one subject with severe renal function impairment with regard to age (± 10 years difference allowed), body weight (± 15% difference allowed), and sex, determined by results at screening.

Additional inclusion criteria for subjects with severe renal function impairment (Group B)

  • Severe renal function impairment as confirmed based on CLcr by the Cockcroft-Gault equation: \<30 mL/min, not on dialysis.
  • The CLcr value should be confirmed (± 25%) on Day -1 since subjects will be dosed more than 10 days after the day of screening.
  • Hematology, clinical chemistry, coagulation and urinalysis test results consistent with severe renal function impairment at screening.
  • Physical examination without clinically relevant abnormalities at screening and on Day -1 (except for those related to severe renal function impairment), which would interfere with the objectives of the study.
  • Stable concomitant medications.

General exclusion criteria for all subjects:

  • Pregnant or lactating women.
  • Clinically relevant history of fainting, collapse, syncope, orthostatic hypotension, or vasovagal
  • History of renal and/or liver transplant.
  • Hepatic cancer, primary biliary cirrhosis or any form of cholestatic disease.
  • Use of drugs which might interfere with the PK of ACT-541468 (moderate to strong inhibitors or inducers).
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.

Additional exclusion criteria for healthy subjects (Group A)

  • History or clinical evidence of any unstable disease and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism or excretion of the study treatment (appendectomy, herniotomy, and cholecystectomy allowed).
  • Intake of any creatine supplement from screening to EOS.

Additional exclusion criteria for subjects with severe renal function impairment (Group B).

  • End-stage renal disease that requires dialysis.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Group A (healthy)

    On Day 1, 8 healthy subjects will receive a single oral dose of 25 mg ACT-541468 in fasted condition.

    Drug: ACT-541468

  • Experimental
    Group B (severe renal function impairment)

    On Day 1, 8 subjects with severe renal function impairment will receive a single oral dose of 25 mg ACT-541468 in fasted condition.

    Drug: ACT-541468

Interventions

  • ACT-541468 25 mg; administered orally

06

What researchers measure

Primary outcomes

  1. AUC of ACT-541468 from time zero to 24 h after study drug administration (AUC0-inf)

    Time frame: Blood samples for PK analysis will be taken at multiple time points after ACT-541468 administration for a total duration of up to 4 days

Secondary outcomes

  1. Number of subjects with treatment-emergent (serious) adverse events (S)AEs

    Time frame: During treatment with ACT-541468 administration for a total duration of up to 4 days

Other outcomes

  1. Maximum plasma concentration (Cmax) of ACT-541468

    Time frame: Blood samples for PK analysis will be taken at multiple time points after ACT-541468 administration for a total duration of up to 4 days

  2. Time to reach maximum plasma concentration (tmax) of ACT-541468

    Time frame: Blood samples for PK analysis will be taken at multiple time points after ACT-541468 administration for a total duration of up to 4 days

  3. Terminal half-life (t½) of ACT-541468

    Time frame: Blood samples for PK analysis will be taken at multiple time points after ACT-541468 administration for a total duration of up to 4 days

  4. Extent of plasma protein binding (PPB; in %)

    PPB % = 100 - (Cu/C×100), with 'Cu' standing for unbound and 'C' for total plasma ACT-541468 concentration.

    Time frame: Blood samples for PK analysis will be taken at multiple time points after ACT-541468 administration for a total duration of up to 4 days

07

Study locations

1 site
  • APEX GmbH
    München, 81241, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2019 to primary completion in Aug 2020, 10 months.

Of 212 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 10 months is above that.

Counting every sponsor, half of 230 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2019
First posted
Jul 18, 2019
StartActual
Sep 24, 2019
Primary completionActual
Aug 14, 2020
CompletionActual
Aug 14, 2020
Last update
Sep 3, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04024332
Responsible party
Sponsor
First posted
Jul 18, 2019
Start date
Sep 24, 2019
Primary completion
Aug 14, 2020
Completion
Aug 14, 2020
Last update
Sep 3, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Daridorexant

Start the discussion